the backpain treatment paradigm is coming. Mesoblast are not the only candidate, but they might be one of the first big breakthroughs.
https://blog.marketresearch.com/lower-back-pain-market-trends
3.55% CAGR expected to 2030:
$5.5b in 2021 [$4.8566b * (1.0355 ^ 4)]. assuming 20% market of the treatment population in US alone in perpetuity at a severe 40% discount rate:
($5.5b * 62.18% * 20% ) / (40% - 3.55%) = $1.87b
assuming 650m shares outstanding = $1870m / 650m = $2.87 per share contribution of CLBP treatment to MSB share price my current guesstimate at present.
the backpain treatment paradigm is coming. Mesoblast are not the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
0.015(1.67%) |
Mkt cap ! $1.044B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 93.5¢ | 89.0¢ | $6.949M | 7.616M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6000 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 134540 | 9 |
View Market Depth
| Last trade - 16.10pm 25/04/2024 (20 minute delay) ? |
|
|||||
|
Last
90.5¢ |
Change
0.015 ( 0.33 %) |
||||
| Open | High | Low | Volume | ||
| 91.0¢ | 93.5¢ | 89.0¢ | 1824946 | ||
| Last updated 15.59pm 25/04/2024 ? | |||||
| MSB (ASX) Chart |